complement
tradit
antivir
natur
compound
act
via
host
target
present
high
barrier
resist
increas
interest
work
report
detect
homoharringtonin
hht
present
effect
antivir
activ
hht
complet
inhibit
infect
vesicular
stomat
viru
vsv
newcastl
diseas
viru
ndv
porcin
epidem
diarrhea
viru
pedv
concentr
nm
cell
cultur
respect
treatment
hht
dose
mgkg
significantli
reduc
viral
load
reliev
sever
symptom
pedvor
ndvinfect
anim
hht
treatment
howev
moder
inhibit
avian
influenza
viru
aiv
infect
suggest
potent
antivir
action
restrict
number
class
rna
virus
studi
also
observ
hht
activ
inhibit
herp
simplex
viru
type
replic
inhibitori
concentr
ic
nm
treatment
hht
nm
led
reduct
three
order
magnitud
moreov
hht
antagon
phosphoryl
level
endogen
exogen
eukaryot
initi
factor
might
regul
select
translat
specif
messeng
rna
mrna
hht
provid
start
point
progress
toward
clinic
develop
broadspectrum
antivir
recent
decad
understand
mechan
regul
translat
made
major
progress
translat
process
consist
three
stepsiniti
elong
termin
initi
phase
carri
two
way
eukaryot
cellscapdepend
capindepend
virus
accomplish
translat
initi
via
capdepend
mechan
vari
util
host
eukaryot
initi
factor
eif
capdepend
mechan
translat
messeng
rna
mrna
molecul
import
mrna
recruit
complex
compos
three
proteinsth
protein
bind
cap
helicas
protein
control
complex
format
interfer
cellular
translat
via
phosphoryl
serin
regul
elong
cycl
best
studi
eukaryot
system
known
virus
reli
cellular
elong
factor
express
viral
genom
virus
lack
translat
apparatu
depend
entir
cellular
translat
machineri
genom
replic
new
particl
assembl
releas
new
viral
progeni
especi
rna
virus
translat
viral
genom
critic
control
point
replic
cycl
sever
drug
develop
take
advantag
vulner
known
ribavirin
guanosin
analog
inhibit
replic
rna
dna
virus
via
distinct
mechan
repress
replic
vesicular
stomat
viru
vsv
via
distinct
mechan
differ
cell
type
depend
intracellular
ribavirin
metabol
among
mechan
action
ribavirin
block
activ
thu
reduc
surviv
signal
silvestrol
multipl
mechan
action
includ
effect
certain
microrna
protein
import
protect
cell
damag
protein
involv
cell
cycl
also
act
specif
inhibitor
potent
inhibitor
ebola
viru
replic
virus
util
host
cell
machineri
translat
facilit
replic
inhibitor
translat
elong
oblig
step
viral
replic
cycl
may
also
provid
gener
antivir
strategi
properli
use
cycloheximid
chx
block
viral
replic
unfortun
cytotox
side
effect
poor
toler
prohibit
develop
drug
lactimidomycin
ltm
prevent
ribosom
leav
start
site
block
first
round
translat
elong
recent
establish
anticanc
agent
potent
inhibit
infect
dengu
viru
rna
virus
cell
cultur
homoharringtonin
hht
known
inhibit
first
cycl
elong
phase
eukaryot
translat
hht
use
china
treatment
chronic
myeloid
leukemia
cml
type
tumor
diseas
past
year
omacetaxin
semisynthet
form
hht
approv
unit
state
us
food
drug
administr
fda
cml
treatment
prosurviv
protein
prooncoprotein
cmyc
critic
regul
promot
surviv
leukemia
cell
hht
could
affect
surviv
leukemia
cell
allow
rapid
loss
shortliv
cmyc
facilit
proapoptot
trigger
leukemia
cell
express
high
level
phosphoryl
inhibit
phosphoryl
repres
uniqu
approach
treatment
cancer
develop
progress
recent
report
hht
target
phosphoryl
serin
residu
result
degrad
phosphoryl
therebi
erad
growth
leukemia
cell
vitro
vivo
present
work
observ
hht
repress
replic
virus
belong
six
famili
hhttreat
embryo
chicken
pig
mice
found
less
suscept
viral
infect
preliminari
result
show
hht
antagon
level
phosphoryl
induc
viral
infect
hht
offer
potenti
develop
broadspectrum
antivir
vero
hela
cell
cultur
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
nonessenti
amino
acid
mm
lglutamin
sodium
pyruv
heatinactiv
fetal
bovin
serum
fb
uml
penicillin
mgml
streptomycin
reagent
purchas
gibco
invitrogen
carlsbad
ca
usa
humidifi
c
co
incub
vesicular
stomat
viru
vsv
strain
indiana
porcin
epidem
diarrhea
viru
pedv
strain
avian
influenza
viru
aiv
strain
herp
simplex
viru
type
strain
f
pseudorabi
viru
prv
strain
fa
obtain
accord
correspond
refer
indic
newcastl
diseas
viru
ndv
strain
gener
insert
addit
transcript
cassett
code
enhanc
gfp
p
gene
ndv
genom
gfpndv
vitro
antivir
assay
cell
seed
cell
per
well
standard
sixwel
plate
infect
virus
h
resuspend
dmem
contain
fb
indic
time
mous
monoclon
antivsvg
use
obtain
santa
cruz
lnc
santa
cruz
ca
usa
antibodi
actin
goat
antimous
secondari
antibodi
conjug
horseradish
peroxidas
hrp
goat
antirabbit
secondari
antibodi
conjug
hrp
obtain
beyotim
biotechnolog
haimen
china
rabbit
polyclon
antibodi
phosphoryl
p
ser
purchas
cell
signal
technolog
danver
usa
rabbit
polyclon
antibodi
purchas
proteintech
wuhan
china
mous
polyclon
antibodi
pedvn
purchas
alpha
diagnost
intern
san
antonio
tx
usa
rabbit
polyclon
antibodi
aivnp
purchas
abcam
cambridg
usa
antibodi
ndvnp
prvgc
preserv
laboratori
antibodi
dilut
phosphatebuff
salin
pb
contain
skim
milk
ph
ribavirin
acyclovir
quercetin
mitogenactiv
protein
kinas
mapk
interact
kinas
kinas
inhibitor
obtain
medchemexpress
monmouth
junction
nj
usa
vero
cell
seed
cell
per
well
plate
infect
tenfold
serial
dilut
h
infect
cell
incub
c
dmem
contain
fb
lowmelt
point
agaros
h
agaros
remov
suction
stain
crystal
violet
ethanol
plaqu
number
count
data
repres
mean
three
independ
experi
cell
mock
infect
expos
viru
mixtur
supplement
dmem
h
inoculum
replac
dmem
contain
fb
incub
indic
time
viru
titrat
perform
cell
seed
plate
cellswel
tenfold
serial
dilut
prepar
sampl
dilut
ad
cell
quadrupl
cytopath
effect
stabil
cell
analyz
use
light
microscopi
log
tcid
ml
determin
use
reedmuench
method
pretreat
assay
cell
monolay
treat
hht
concentr
nm
vsv
nm
pedv
h
c
prior
wash
twice
pb
infect
viru
multipl
infect
moi
vsv
pedv
viru
adsorpt
period
infect
cell
incub
c
dmem
supplement
fb
h
viral
yield
medium
determin
tcid
cotreat
posttreat
assay
cell
infect
viru
h
adsorpt
hht
ad
differ
time
point
infect
cell
harvest
h
post
infect
quantif
viral
yield
cell
collect
centrifug
dissolv
lysi
buffer
presenc
proteas
inhibitor
cocktail
final
disrupt
sonic
cell
suspens
fraction
centrifug
g
min
c
solubil
protein
harvest
electrophores
denatur
polyacrylamid
gel
electroblot
onto
polyvinyliden
fluorid
pvdf
membran
react
antibodi
indic
protein
band
detect
secondari
antibodi
conjug
horseradish
peroxidas
hrp
min
room
temperatur
actin
use
load
control
replic
cultur
harvest
total
rna
extract
use
trizol
reagent
invitrogen
accord
manufactur
protocol
twostep
rtpcr
sybr
green
technolog
appli
roch
diagnost
mannheim
germani
perform
use
sybr
green
supermix
toyobo
osaka
japan
accord
manufactur
protocol
measur
transcript
level
sever
gene
interest
primer
use
follow
ndvnp
ttt
tgc
taa
cag
tgt
gcc
forward
atc
ttc
aac
ccc
agc
tgt
revers
pedvn
ctg
ggt
tgc
taa
aga
agg
forward
ctg
ggg
agc
tgt
tga
gag
revers
actin
cgt
tga
cat
ccg
taa
aga
forward
cta
gga
gcc
aga
gca
gta
revers
glyceraldehyd
dehydrogenas
gapdh
gat
cat
cag
caa
tgc
ctc
forward
tga
gtc
ctt
cca
cga
tac
revers
rel
fold
chang
automat
calcul
step
one
plu
realtim
pcr
system
softwar
appli
biosystem
foster
citi
ca
usa
follow
method
actin
also
determin
use
intern
control
inocul
mixtur
hht
aladdin
puriti
ndv
plaqueform
unit
pfu
aiv
pfu
inject
allanto
caviti
specif
pathogenfre
spf
chicken
egg
egg
incub
differ
time
allanto
fluid
harvest
measur
viral
yield
describ
previou
report
chicken
embryo
allanto
fluid
harvest
twofold
serial
dilut
steril
salin
dilut
mix
equal
volum
wash
red
blood
cell
rbc
chicken
maximum
dilut
allanto
fluid
still
result
complet
agglutin
rbc
suspens
record
ha
unit
hau
viru
titer
spf
chicken
challeng
intramuscular
inject
pfu
gfpndv
treat
mgkg
hht
pb
three
day
ndvnp
mrna
liver
lung
quantifi
qrtpcr
seven
day
post
infect
spf
piglet
inject
intramuscularli
pfu
pedv
mgkg
hht
three
sequenti
day
pedvn
mrna
intestin
quantifi
qrtpcr
five
day
post
infect
total
rna
prepar
mg
tissu
homogen
trizol
accord
manufactur
instruct
dnaseitr
rna
reversetranscrib
complementari
dna
cdna
twostep
rtpcr
sybr
green
technolog
appli
roch
perform
use
sybr
green
supermix
toyobo
accord
manufactur
protocol
mice
intranas
inject
pfu
aiv
intraperiton
inject
mgkg
hht
two
sequenti
day
repres
lung
section
group
subject
immunohistochem
analysi
hematoxylin
eosin
h
e
stain
two
four
day
post
infect
anim
observ
daili
clinic
sign
anim
euthan
inject
pentobarbit
sodium
intraven
reduc
stress
anim
euthanasia
carri
soundproof
room
avoid
panic
live
anim
anim
protocol
approv
anim
welfar
committe
china
agricultur
univers
follow
anim
hous
pathogenfre
food
water
lightcycl
condit
aivinfect
mice
indic
sacrif
indic
day
post
infect
lung
harvest
fix
neutral
buffer
formalin
organ
paraffinembed
section
stain
hematoxylin
eosin
subject
immunohistochem
analysi
use
antibodi
aivnp
express
nucleoprotein
np
semiquantit
analyz
light
microscop
magnif
histopatholog
imag
observ
light
microscop
magnif
patholog
chang
observ
olympu
microscop
olympu
tokyo
japan
vector
purchas
clontech
mountain
view
ca
usa
flagtag
flagtag
mutant
clone
vector
use
design
primer
eukaryot
express
plasmid
flagtag
flagtag
mutant
transfect
cell
aid
lipofectamin
ltx
invitrogen
accord
manufactur
instruct
mtt
assay
conduct
accord
manufactur
beyotim
biotechnolog
protocol
briefli
cell
plate
treat
increas
dose
hht
c
co
h
mtt
solut
ad
well
sampl
incub
h
medium
remov
formazan
solut
ad
well
optic
densiti
od
valu
measur
test
wave
length
nm
use
multiskan
ascent
micropl
photomet
thermo
fisher
scientif
waltham
usa
result
express
mean
standard
deviat
sd
statist
analys
perform
use
prism
graphpad
softwar
la
jolla
ca
usa
signific
determin
oneway
analysi
varianc
anova
twoway
anova
dunnett
multiplecomparison
test
partial
correl
analys
evalu
use
unpair
student
ttest
anim
research
project
sanction
beij
laboratori
anim
welfar
ethic
committe
approv
anim
ethic
committe
china
agricultur
univers
approv
number
perform
accord
regul
experiment
anim
beij
author
prototyp
rhabdoviru
vsv
wide
studi
model
viral
protein
translat
control
earli
report
show
ribavirin
inhibit
vsv
titer
cell
order
magnitud
paper
evalu
effect
plant
alkaloid
hht
figur
natur
product
first
discov
cephalotaxu
harringtonii
vsv
replic
measur
decreas
cell
viabil
detect
concentr
therefor
hht
concentr
administ
experi
describ
test
potenti
dosedepend
antivir
activ
cell
infect
vsv
presenc
hht
ribavirin
increas
concentr
observ
viral
yield
reduc
order
magnitud
treat
hht
nm
viral
yield
dramat
reduc
cell
treat
hht
nm
measur
decreas
cell
viabil
detect
ribavirin
display
antivir
activ
concentr
figur
analyz
specif
hht
viral
replic
investig
impact
level
viral
protein
western
blot
observ
strong
reduct
viral
protein
g
level
vsv
vsvg
h
post
infect
hpi
treatment
hht
nm
figur
timeofaddit
studi
conduct
identifi
window
vsv
replic
cycl
hht
exert
antivir
effect
result
show
pretreat
cell
hht
h
prior
vsv
infect
produc
minim
inhibitori
effect
viral
infect
suggest
hht
inhibit
vsv
entri
process
figur
complet
reduct
viral
yield
observ
hht
ad
time
infect
hpi
onward
addit
hht
hpi
led
strong
viral
reduct
order
magnitud
experiment
condit
strong
reduct
vsvg
level
observ
cotreat
posttreat
h
vsv
infect
figur
result
indic
hht
act
viral
replic
cycl
viral
entri
cell
expos
vsv
moi
treat
hht
nm
differ
time
point
simultan
infect
hpi
viral
yield
medium
determin
tcid
experi
perform
two
time
three
replic
experi
valu
repres
mean
sd
statist
analysi
evalu
oneway
analysi
varianc
dunnett
multiplecomparison
test
p
p
compar
pbstreat
group
experiment
condit
electrophoret
separ
protein
analyz
immunoblot
antibodi
vsvg
actin
e
newcastl
diseas
paramyxovirida
famili
one
import
avian
diseas
poultri
present
research
effort
cell
infect
gfpndv
presenc
increas
dose
hht
observ
hht
nm
greatli
reduc
product
recombin
ndv
express
green
fluoresc
protein
gfp
determin
light
microscopi
figur
hela
cell
display
differ
morpholog
number
compar
mock
infect
sampl
treat
hht
nm
correspondingli
hht
treatment
show
dosedepend
reduct
infect
rate
shown
figur
estim
inhibitori
concentr
ic
valu
nm
ic
nm
observ
measur
decreas
cell
viabil
detect
concentr
figur
also
observ
strong
reduct
ndvnp
level
cell
treat
hht
nm
figur
hela
cell
seed
cell
per
well
plate
expos
gfpndv
moi
presenc
hht
increas
concentr
h
express
gfp
directli
observ
use
camera
fluoresc
microscopi
olympu
microscop
magnif
af
assess
light
microscopi
f
one
imag
repres
three
experiment
condit
infect
rate
hht
gfpndv
infect
express
percent
reduct
fluoresc
activ
infect
cell
without
hht
treatment
set
half
maxim
inhibitori
concentr
ic
calcul
indic
fine
dot
line
experi
perform
two
time
three
replic
experi
valu
repres
mean
sd
bottom
effect
hht
hela
cell
viabil
determin
assess
indic
figur
statist
analysi
evalu
oneway
analysi
varianc
dunnett
multiplecomparison
test
p
compar
control
group
b
hela
cell
seed
cell
per
well
sixwel
plate
experiment
condit
cell
lysat
harvest
electrophoret
separ
protein
analyz
immunoblot
antibodi
viral
protein
ndvnp
actin
control
c
inhibitori
effect
hht
ndv
infect
chicken
embryo
hht
differ
concentr
pb
volum
inject
allanto
caviti
specif
pathogenfre
spf
chicken
egg
simultan
gfpndv
inocul
plaqueform
unit
pfu
egg
incub
h
analyz
time
viral
yield
allanto
fluid
determin
log
hemagglutin
unit
hau
graph
repres
averag
three
embryo
per
experiment
group
error
bar
denot
standard
error
mean
experi
perform
triplic
statist
analysi
evalu
twoway
analysi
varianc
dunnett
multiplecomparison
test
p
p
compar
pbstreat
egg
e
f
vivo
antivir
efficaci
fourto
fiveweekold
spf
chicken
challeng
via
intramuscular
im
rout
pfu
gfpndv
simultan
mgkgday
hht
pb
contain
dmso
volum
three
day
oneday
interv
ndvnp
messeng
rna
mrna
liver
lung
quantifi
qrtpcr
seven
day
post
infect
graph
repres
averag
anim
per
experiment
group
valu
repres
mean
sd
experi
perform
two
time
three
replic
experi
valu
repres
mean
sd
statist
analysi
evalu
oneway
analysi
varianc
dunnett
multiplecomparison
test
p
p
compar
pbstreat
egg
e
experiment
condit
ndvnp
mrna
three
randomli
drawn
blood
sampl
analyz
qrtpcr
group
repres
independ
experi
experi
perform
triplic
statist
analysi
evalu
use
unpair
student
ttest
p
compar
pbstreat
chicken
f
examin
abil
hht
reduc
gfpndv
replic
chicken
embryo
wide
use
vivo
model
viral
infect
gfpndv
differ
dose
hht
inject
allanto
caviti
spf
chicken
embryo
viral
yield
allanto
fluid
embryo
measur
ha
assay
shown
figur
hht
dose
mgkg
slight
effect
viral
infect
mgkg
hht
reduc
hau
valu
one
three
order
magnitud
hpi
respect
remark
mgkg
hht
provid
optim
inhibitori
activ
complet
inhibit
viral
infect
final
studi
whether
hht
display
potent
antivir
activ
ndv
chicken
shown
figur
f
mgkg
hht
significantli
decreas
mrna
level
ndvnp
liver
lung
figur
blood
figur
hhttreat
anim
exhibit
patholog
chang
tissu
symptom
diarrhea
droop
result
indic
hht
effect
reduc
viral
load
ndvinfect
cell
embryo
chicken
studi
also
observ
ribavirin
inhibit
gfpndv
replic
ic
valu
tabl
ic
half
maxim
cytotox
concentr
cc
well
select
index
valu
show
hht
treatment
indic
dosag
effect
ribavirin
without
affect
cell
viabil
pedv
coronavirida
famili
caus
viremia
high
mortal
rate
newborn
piglet
efficaci
avail
commerci
vaccin
limit
protect
immun
insuffici
observ
viral
yield
reduc
order
magnitud
treatment
hht
nm
vero
cell
complet
suppress
treatment
hht
nm
figur
measur
decreas
cell
viabil
detect
concentr
figur
quercetin
natur
compound
affect
initi
stage
pedv
infect
interf
viral
replic
ic
valu
hht
quercetin
pedv
respect
tabl
strong
reduct
pedvn
protein
mrna
level
treatment
cell
hht
also
observ
figur
hht
nm
ad
differ
time
infect
cell
pedv
similar
result
shown
figur
less
infect
rate
found
hht
ad
hpi
figur
strong
reduct
pedvn
level
also
observ
figur
figur
b
experiment
condit
electrophoret
separ
protein
analyz
immunoblot
antibodi
viral
protein
pedvn
actin
bottom
total
rna
isol
pedvn
mrna
quantifi
qrtpcr
normal
actin
statist
analysi
evalu
oneway
analysi
varianc
dunnett
multiplecomparison
test
p
compar
pbstreat
group
c
e
timeofaddit
studi
vero
cell
treat
hht
nm
differ
time
point
infect
hpi
infect
rate
hht
pedv
infect
express
percentag
infect
cell
without
hht
treatment
set
experi
perform
two
time
three
replic
experi
valu
repres
mean
sd
statist
analysi
evalu
oneway
analysi
varianc
dunnett
multiplecomparison
test
p
compar
pbstreat
group
experiment
condit
cell
harvest
electrophoret
separ
protein
analyz
immunoblot
antibodi
pedvn
actin
e
f
g
vivo
antivir
efficaci
threeto
fivedayold
spf
piglet
challeng
via
intramuscular
im
inject
pfu
pedv
time
treat
mgkgday
hht
pb
contain
dmso
volum
three
sequenti
day
pedvn
mrna
intestin
quantifi
qrtpcr
five
day
post
infect
graph
repres
averag
anim
per
experiment
group
valu
repres
mean
sd
experi
perform
two
time
three
replic
experi
statist
analysi
evalu
oneway
analysi
varianc
dunnett
multiplecomparison
test
p
compar
pbstreat
piglet
f
experiment
condit
pedvn
mrna
three
four
randomli
drawn
blood
sampl
also
analyz
qrtpcr
group
repres
independ
experi
experi
perform
triplic
statist
analysi
evalu
use
unpair
student
ttest
p
compar
pbstreat
piglet
g
examin
abil
hht
reduc
pedv
infect
piglet
found
treatment
mgkg
hht
led
sever
side
effect
fatal
anim
hht
dose
mgkg
provid
optim
inhibitori
activ
without
death
administ
subsequ
experi
detect
hht
treatment
greatli
decrease
mrna
level
pedvn
intestin
figur
blood
figur
hhttreat
anim
exhibit
patholog
chang
tissu
symptom
diarrhea
cachexia
result
indic
hht
effect
reduc
viral
load
pedv
infect
cell
anim
analyz
antivir
activ
hht
aiv
orthomyxovirida
famili
examin
abil
hht
reduc
aiv
replic
mice
use
immunohistochemistri
analysi
h
e
stain
detect
distribut
aiv
figur
g
inflamm
erythrocyt
infiltr
h
lung
infect
mice
obviou
reduct
number
aiv
posit
cell
observ
mice
treat
hht
dose
mgkg
e
moreov
hht
treatment
two
day
decreas
local
inflammatori
reaction
aggrav
overal
inflamm
f
hht
treatment
four
day
result
moder
attenu
inflamm
j
obviou
inflammatori
reaction
seen
mice
treat
hht
day
administr
k
l
result
indic
hht
effici
affect
aivinduc
inflamm
damag
also
studi
effect
hht
aiv
embryo
shown
figur
mgkg
hht
reduc
hau
valu
order
magnitud
hpi
mgkg
hht
reduc
hau
valu
order
magnitud
hpi
respect
taken
togeth
conclud
given
dose
hht
produc
inhibitori
effect
aiv
compar
action
rna
virus
consid
paper
sixto
eightweekold
balbc
mice
mock
infect
b
intranas
inject
pfu
aiv
intraperiton
ip
inject
mgkgday
hht
e
f
j
pb
contain
dmso
c
g
h
volum
two
sequenti
day
repres
lung
section
group
subject
immunohistochem
analysi
antibodi
aivnp
left
hematoxylin
eosin
h
e
stain
right
two
four
day
post
infect
hht
day
treatment
k
l
arrow
right
panel
indic
inflammatori
cell
infiltr
erythrocyt
infiltr
drop
mucou
epithelium
bronchia
spf
chicken
egg
challeng
aiv
inocul
pfu
simultan
treat
mgkg
hht
pb
contain
dmso
egg
incub
h
analyz
time
assess
describ
figur
p
compar
dmsotreat
egg
b
test
inhibitori
effect
hht
dna
virus
prv
member
herpesvirida
famili
observ
treatment
hht
nm
led
reduct
one
three
order
magnitud
vero
cell
respect
figur
strong
reduct
level
also
observ
figur
acyclovir
inhibitor
viral
dna
replic
approv
medicin
infect
therapi
ic
valu
hht
acyclovir
nm
nm
respect
tabl
also
found
hht
nm
produc
inhibit
viral
yield
order
magnitud
vero
cell
respect
prv
figur
hht
treatment
nm
led
strong
reduct
prvgc
level
figur
obviou
differ
abil
hht
reduc
viral
replic
prv
report
hht
reduc
phosphoryl
level
well
level
present
work
detect
accumul
gradual
reduc
cell
treat
increas
dose
hht
figur
lane
also
found
level
gradual
reduc
lane
cellular
total
level
unaffect
posit
control
treat
inhibitor
kinas
upstream
kinas
prevent
phosphoryl
ser
without
effect
total
protein
level
lane
explor
whether
inhibitori
effect
hht
viral
infect
relat
phosphoryl
result
show
level
endogen
increas
upon
pedv
prv
figur
lane
infect
furthermor
high
level
parallel
level
viral
protein
gradual
reduc
treatment
increas
dose
hht
lane
result
demonstr
antivir
effect
hht
might
associ
function
inhibitor
clarifi
whether
hht
regul
level
associ
viral
replic
two
construct
encod
wildtyp
flagtag
phosphorylationincompet
variant
transient
transfect
follow
infect
shown
figur
ectop
express
wildtyp
lane
lane
greatli
improv
level
also
upregul
express
viral
lane
furthermor
detect
hht
treatment
decreas
accumul
induc
ectop
express
wildtyp
coincid
decreas
viral
propag
lane
taken
togeth
result
shown
figur
e
indic
hht
attenu
phosphoryl
level
endogen
exogen
counteract
replic
high
virul
virus
absenc
effect
therapi
pose
ongo
threat
public
health
due
intrins
high
mutat
rate
rna
virus
resist
antivir
drug
act
viral
target
occur
rapidli
focu
antivir
target
host
factor
thu
expect
advantag
strategi
escap
mutat
rarer
cellular
translat
necessari
viral
replic
inhibit
protein
product
may
impair
delay
prolifer
viral
pathogen
howev
inhibit
host
factor
often
problemat
issu
drug
develop
due
pleiotrop
unwant
side
effect
hht
high
dose
mgkg
found
previou
work
complet
erad
acut
myeloid
leukemia
vivo
mice
mice
obtain
longterm
diseasefre
surviv
fact
data
patient
without
viral
infect
suggest
hht
gener
safe
vivo
effect
cytotox
hht
piglet
chicken
embryo
chicken
previous
report
studi
hht
dose
mgkg
piglet
mgkg
chicken
effect
repress
viral
product
treat
anim
surviv
without
pathogen
chang
tissu
symptom
addit
hht
display
toxic
dose
piglet
chicken
treat
mgkg
respect
hht
provid
promis
start
point
advanc
toward
clinic
develop
antivir
antivir
efficaci
hht
hepat
b
viru
hbv
dna
level
bovin
viral
diarrhea
viru
bvdv
infect
previous
describ
hht
concentr
protect
effect
hht
produc
inhibit
viral
yield
order
magnitud
chikungunya
viru
treatment
hht
nm
recent
shown
produc
highmagnitud
inhibit
mous
hepat
coronaviru
mhv
vitro
inhibit
viral
translat
current
studi
detect
hht
present
broad
antivir
activ
host
cell
hht
complet
inhibit
infect
rna
virus
vsv
ndv
pedv
nm
cell
cultur
respect
timeofaddit
studi
reveal
hht
remain
potent
even
administr
h
post
infect
comparison
hht
treatment
moder
inhibit
infect
aiv
given
dose
potent
antivir
action
hht
may
restrict
number
class
rna
virus
time
depend
also
studi
detect
hht
treatment
nm
produc
inhibit
viral
yield
order
magnitud
dna
virus
prv
hpi
respect
interest
note
cell
infect
prv
h
presenc
hht
nm
show
strong
reduct
viral
replic
result
indic
hht
effect
timedepend
hht
util
dna
virus
earliest
feasibl
stage
replic
consid
select
antivir
activ
hypothes
hht
may
sensit
cell
prevent
viral
replic
addit
complementari
mechan
although
virus
complet
depend
upon
host
translat
machineri
use
divers
mechan
translat
initi
total
activ
requir
prolifer
tumor
normal
cell
wherea
phosphoryl
essenti
normal
cell
prolifer
surviv
specif
requir
cancer
cell
stimul
phosphoryl
correl
facilit
translat
replic
virus
includ
murin
coronaviru
herpesviru
contrast
dephosphoryl
occur
infect
influenza
viru
vsv
encephalomyocard
viru
emcv
sometim
phosphoryl
requir
support
viral
replic
hepat
e
viru
notabl
fibroblast
mice
serin
posit
replac
alanin
low
level
less
suscept
viru
infect
includ
vsv
emcv
therefor
phosphoryl
statu
act
determin
host
suscept
viru
current
studi
hht
found
attenu
phosphoryl
level
endogen
exogen
accord
viral
protein
pedv
prv
result
demonstr
inhibitori
effect
hht
viral
infect
associ
phosphoryl
phosphoryl
would
rather
favor
translat
select
mrna
impair
translat
initi
global
level
upon
viral
infect
thu
promis
find
possibl
therapeut
agent
involv
select
translat
viral
replic
specif
block
host
cell
translat
unaffect
research
cours
far
complet
worthi
develop
hht
broad
activ
offer
interest
perspect
repurpos
antitumor
drug
antivir
compar
tradit
drug
discoveri
develop
reposit
drug
offer
signific
advantag
includ
minim
risk
failur
sinc
toxic
toler
pharmacokinet
properti
drug
alreadi
known
therefor
cost
time
need
bring
drug
market
significantli
reduc
furthermor
short
durat
therapysever
day
suffici
treat
acut
viral
infect
chronic
diseas
might
requir
month
yearswould
presum
reduc
drug
load
therefor
drugrel
toxic
possibl
side
effect
broad
inhibitori
effect
hht
viral
replic
warrant
evalu
natur
compound
firstlin
therapeut
combat
virus
includ
emerg
pathogen
speci
combin
therapi
target
viral
compon
cellular
mechan
might
improv
antivir
efficaci
reduc
viral
resist
minim
toxic
side
effect
control
viral
infect
epidem
viral
diseas
conclus
hht
potent
inhibit
viral
replic
vsv
ndv
pedv
prv
comparison
hht
treatment
moder
inhibit
infect
aiv
given
dose
furthermor
hhttreat
embryo
chicken
piglet
less
suscept
viral
infect
ndv
ndv
pedv
addit
preliminari
result
show
hht
antagon
phosphoryl
level
endogen
exogen
vero
hela
cell
potent
antivir
action
hht
restrict
number
class
virus
detail
clarif
still
need
